Back to Search
Test Name REF LAB LUNG CANCER MUTATION PANEL (EGFR KRAS ALK)
Orderable CPT -
OVT 123002559
Synonyms -
Result Test Name QUEST EGFR MUTATION ANALYSIS
Laboratory QUEST LAB
Result Test Code 123924767
Laboratory Test Name QUEST LUNG CANCER MUTATION PANEL (EGFR KRAS ALK)
Reportable Test Name -
Result LOINC 21665-5
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 12 unstained charged (+) slides Minimum Volume 8 unstained charged (+) slides Collection Instructions Do not reject specimens. Send to laboratory for screening.
Container Temp Room Temperature (1)
Container Volume -
Test Info Lung Cancer Mutation Panel (EGFR KRAS ALK) - This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Shipping Instructions Transport Container Formalin-fixed paraffin embedded tissue block Transport Temperature Room temperature Specimen Stability Room temperature: 5 years Refrigerated: 5 years Frozen: Unacceptable
Result Test Name QUEST INTERPRETATION
Laboratory QUEST LAB
Result Test Code 12386005624
Laboratory Test Name QUEST LUNG CANCER MUTATION PANEL (EGFR KRAS ALK)
Reportable Test Name -
Result LOINC 47969-1
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 12 unstained charged (+) slides Minimum Volume 8 unstained charged (+) slides Collection Instructions Do not reject specimens. Send to laboratory for screening.
Container Temp Room Temperature (1)
Container Volume -
Test Info Lung Cancer Mutation Panel (EGFR KRAS ALK) - This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Shipping Instructions Transport Container Formalin-fixed paraffin embedded tissue block Transport Temperature Room temperature Specimen Stability Room temperature: 5 years Refrigerated: 5 years Frozen: Unacceptable
Result Test Name QUEST SPECIMEN TYPE/SOURCE
Laboratory QUEST LAB
Result Test Code 123924765
Laboratory Test Name QUEST LUNG CANCER MUTATION PANEL (EGFR KRAS ALK)
Reportable Test Name -
Result LOINC 31208-2
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 12 unstained charged (+) slides Minimum Volume 8 unstained charged (+) slides Collection Instructions Do not reject specimens. Send to laboratory for screening.
Container Temp Room Temperature (1)
Container Volume -
Test Info Lung Cancer Mutation Panel (EGFR KRAS ALK) - This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Shipping Instructions Transport Container Formalin-fixed paraffin embedded tissue block Transport Temperature Room temperature Specimen Stability Room temperature: 5 years Refrigerated: 5 years Frozen: Unacceptable
Result Test Name BLOCK/SPECIMEN ID
Laboratory QUEST LAB
Result Test Code 123013765
Laboratory Test Name QUEST LUNG CANCER MUTATION PANEL (EGFR KRAS ALK)
Reportable Test Name -
Result LOINC -
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 12 unstained charged (+) slides Minimum Volume 8 unstained charged (+) slides Collection Instructions Do not reject specimens. Send to laboratory for screening.
Container Temp Room Temperature (1)
Container Volume -
Test Info Lung Cancer Mutation Panel (EGFR KRAS ALK) - This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Shipping Instructions Transport Container Formalin-fixed paraffin embedded tissue block Transport Temperature Room temperature Specimen Stability Room temperature: 5 years Refrigerated: 5 years Frozen: Unacceptable
Result Test Name CLINICAL INDICATION:
Laboratory QUEST LAB
Result Test Code 123012211
Laboratory Test Name QUEST LUNG CANCER MUTATION PANEL (EGFR KRAS ALK)
Reportable Test Name -
Result LOINC 55752-0
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 12 unstained charged (+) slides Minimum Volume 8 unstained charged (+) slides Collection Instructions Do not reject specimens. Send to laboratory for screening.
Container Temp Room Temperature (1)
Container Volume -
Test Info Lung Cancer Mutation Panel (EGFR KRAS ALK) - This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Shipping Instructions Transport Container Formalin-fixed paraffin embedded tissue block Transport Temperature Room temperature Specimen Stability Room temperature: 5 years Refrigerated: 5 years Frozen: Unacceptable
Result Test Name QUEST KRAS MUTATION ANALYSIS
Laboratory QUEST LAB
Result Test Code 123924770
Laboratory Test Name QUEST LUNG CANCER MUTATION PANEL (EGFR KRAS ALK)
Reportable Test Name -
Result LOINC 21702-6
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 12 unstained charged (+) slides Minimum Volume 8 unstained charged (+) slides Collection Instructions Do not reject specimens. Send to laboratory for screening.
Container Temp Room Temperature (1)
Container Volume -
Test Info Lung Cancer Mutation Panel (EGFR KRAS ALK) - This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Shipping Instructions Transport Container Formalin-fixed paraffin embedded tissue block Transport Temperature Room temperature Specimen Stability Room temperature: 5 years Refrigerated: 5 years Frozen: Unacceptable
Result Test Name QUEST SPECIMEN TYPE/SOURCE
Laboratory QUEST LAB
Result Test Code 12386025567
Laboratory Test Name QUEST LUNG CANCER MUTATION PANEL (EGFR KRAS ALK)
Reportable Test Name -
Result LOINC 60033-8
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 12 unstained charged (+) slides Minimum Volume 8 unstained charged (+) slides Collection Instructions Do not reject specimens. Send to laboratory for screening.
Container Temp Room Temperature (1)
Container Volume -
Test Info Lung Cancer Mutation Panel (EGFR KRAS ALK) - This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Shipping Instructions Transport Container Formalin-fixed paraffin embedded tissue block Transport Temperature Room temperature Specimen Stability Room temperature: 5 years Refrigerated: 5 years Frozen: Unacceptable
Result Test Name FISH ALK 2P23 REA LUNG CANCER (NSCLC)
Laboratory QUEST LAB
Result Test Code 123040403
Laboratory Test Name QUEST LUNG CANCER MUTATION PANEL (EGFR KRAS ALK)
Reportable Test Name -
Result LOINC -
Collection Container PATH CONTAINER
Units -
Collection Requirements Preferred Specimen(s) Formalin-fixed paraffin-embedded tissue Alternative Specimen(s) 12 unstained charged (+) slides Minimum Volume 8 unstained charged (+) slides Collection Instructions Do not reject specimens. Send to laboratory for screening.
Container Temp Room Temperature (1)
Container Volume -
Test Info Lung Cancer Mutation Panel (EGFR KRAS ALK) - This panel is comprised of mutational analysis of the EGFR and KRAS genes and assessment for ALK locus rearrangement using an FDA-cleared FISH assay. These are the most common tumor-associated genetic changes that have been shown to have prognostic and therapeutic consequences in non-small cell lung cancer (NSCLC) and help guide therapy. Patients with EGFR mutations are generally responsive to EGFR-directed kinase inhibitors whereas those with evidence of ALK gene rearrangements are candidates for treatment with the ALK inhibitor crizotinib. The presence of KRAS mutation in lung adenocarcinoma predicts for non-response to kinase inhibitors and for tumors with inferior outcome.
Shipping Instructions Transport Container Formalin-fixed paraffin embedded tissue block Transport Temperature Room temperature Specimen Stability Room temperature: 5 years Refrigerated: 5 years Frozen: Unacceptable